FINWIRES · TerminalLIVE
FINWIRES

EyePoint Pharmaceuticals Agrees to Settle US False Claims Act Allegations

By

EyePoint Pharmaceuticals (EYPT) has agreed to pay about $4.66 million to settle allegations that it violated the False Claims Act by providing kickbacks to encourage ambulatory service centers to buy and dispense the Dexycu injectable drug from January 2019 to March 1, 2023, the US Department of Justice said Friday.

As part of the settlement, EyePoint entered into a five-year corporate integrity agreement, agreed to pay an additional $21,518.68 to certain participating states, and resolved whistleblower claims, with the relator set to receive about $792,000, according to a statement.

EyePoint Pharmaceuticals shares were up 4.2% in Friday trading.

Price: $13.59, Change: $+0.55, Percent Change: +4.22%

Related Articles

Wire

STAAR Surgical Reports Higher Q2 Preliminary Net Sales

STAAR Surgical (STAA) reported Q2 preliminary net sales late Thursday of more than $90 million, up from $44.3 million a year earlier.Analysts polled by FactSet are looking for $90.2 million.Net sales in the Middle East, certain parts of the EMEA and Asia-Pacific regions, were affected by geopolitical and macro headwinds, the company said, adding that, if the conditions persist or worsen, its sales growth could continue to be negatively affected.Shares were down about 13% in after-hours trading.

$STAA
Wire

Alcoa Fiscal Q2 Adjusted Earnings, Revenue Rise

Alcoa (AA) reported fiscal Q2 non-GAAP net income late Thursday of $2.12 per diluted share, up from $0.39 a year earlier.Analysts polled by FactSet expected $2.25.Revenue for the quarter ended June 30 was $3.97 billion, up from $3.02 billion a year earlier.Analysts expected $3.99 billion.

$AA
Wire

Netflix Fiscal Q2 Earnings, Revenue Rise; Q3 Guidance Set

Netflix (NFLX) reported fiscal Q2 earnings late Thursday of $0.80 per diluted share, up from $0.72 a year earlier.Analysts polled by FactSet expected $0.79.Revenue for the three months ended June 30 was $12.56 billion, up from $11.08 billion a year earlier.Analysts expected $12.58 billion.For Q3, the company expects EPS of $0.82 on revenue of $12.86 billion. Analysts expect EPS of $0.84 on revenue of $13 billion.For the full-year 2026, the company now expects revenue of $51 billion to $51.4 billion. It earlier expected $50.7 billion to $51.7 billion. Analysts expect $51.38 billion.

$NFLX